Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202402357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Jinzhao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, 999077, China. Hauptthemen laut MEDLINE: Photochemotherapy, Breast Neoplasms, TOR Serine-Threonine Kinases, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Conventional photodynamic therapy (PDT) in cancer treatment needs to utilize oxygen to produce reactive oxygen species to eliminate malignant tissues. However, oxygen consumption in tumor microenvironment exacerbates cancer cell hypoxia and may promote vasculature angiogenesis. Since the mammalian target of rapamycin (mTOR) signaling pathway plays a vital role in endothelial cell proliferation and fibrosis, mTOR inhibitor drugs hold the potential to reverse hypoxia‐evoked angiogenesis for improved PDT effect. In this study, a carrier‐free nanodrug formulation composed of Torin 1 as mTORC1/C2 dual inhibitor and Verteporfin as a photosensitizer and Yes‐associated protein inhibitor is developed. These two drug molecules can self‐assemble into stable nanoparticles through π–π stacking and hydrophobic interactions with good long‐term stability. The nanodrugs can prompt synergistic apoptosis, combinational anti‐angiogenesis, and strong immunogenic cell death effects upon near‐infrared light irradiation in vitro. Furthermore, the nanosystem also exhibits improved antitumor effect, anti‐cancer immune response, and distant tumor inhibition through tumor microenvironment remodeling in vivo. In this way, the nanodrugs can reverse PDT‐elicited angiogenesis and promote cancer immunotherapy to eliminate tumor tissues and prevent metastasis. This nanosystem provides insights into integrating mTOR inhibitors and photosensitizers for safe and effective breast cancer treatment in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, 999077, China.
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 999077, China.
- Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong, 999077, China.
ORCID-Profile: Weiping Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Lyu, Q., Wu, M., Zhou, Y., Wang, T., Zhang, Y., Fan, N., Yang, C., & Wang, W. (2024). Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402357
Vancouver
Liu J, Lyu Q, Wu M, Zhou Y, Wang T, Zhang Y, et al. Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202402357
BibTeX
@article{Liu2024,
author = {Liu, Jinzhao and Lyu, Qingyang and Wu, Meicen and Zhou, Yang and Wang, Tianyi and Zhang, Yichi and Fan, Ni and Yang, Chang and Wang, Weiping},
title = {Integrating mTOR Inhibition and Photodynamic Therapy Based on Carrier‐Free Nanodrugs for Breast Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202402357}
}
EUVIMED